Tmunity Therapeutics Funding & Investors
Philadelphia, PA
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation and direction in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing toward the clinic personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease. The founding team includes experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, who collectively have an unparalleled track record of executing safe and effective cell and gene therapy clinical trials. In addition, Tmunity’s manufacturing platform has a proven track record of success in supporting multi-center clinical studies across diverse therapeutic indications.
tmunity.comTotal Amount Raised: $230,000,000
Tmunity Therapeutics Funding Rounds
Series B
$75,000,000
Series B Investors
Andreessen HorowitzGilead SciencesBe The Match BioTherapiesWestlake Village BioPartnersBrightEdge FundPenn Medicine Co-Investment ProgramSeries A
$35,000,000
Series A Investors
Gilead SciencesPing An VenturesParker Institute for Cancer ImmunotherapyBe The Match BioTherapiesLilly Asia VenturesKleiner PerkinsPenn Medicine Co-Investment ProgramUniversity of Pennsylvania (Penn)Series A
$100,000,000
Series A Investors
Ping An VenturesParker Institute for Cancer ImmunotherapyGilead SciencesBe The Match BioTherapiesLilly Asia VenturesUniversity of Pennsylvania (Penn)Series Unknown
$10,000,000
Series Unknown Investors
Lilly Asia VenturesPenn Medicine Co-Investment ProgramSeed
$10,000,000
Seed Investors
Parker Institute for Cancer ImmunotherapyPenn Medicine Co-Investment Program